BIPHASIC INSULIN ASPART 30 VS. NPH PLUS REGULAR HUMAN INSULIN IN TYPE 2 DIABETIC PATIENTS: A COST-EFFECTIVENESS STUDY

被引：0
|
作者：
Farshchi, A. [1 ]
Oskuee, M. [2 ]
Rashed, M. [2 ]
Aghili, R. [3 ]
Kebriaeezadeh, A. [1 ]
Esteghamati, A. [4 ]
机构：
[1] Univ Tehran Med Sci, Sch Pharm, Tehran, Iran
[2] Azad Univ Pharmaceut Sci, Tehran, Iran
[3] Univ Tehran Med Sci, Endocrine Res Ctr Firouzgar, Tehran, Iran
[4] Univ Tehran Med Sci, Vali Asr Hosp, Tehran, Iran
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A90 / A91
页数：2
相关论文
共 50 条
  • [1] Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
    Amir Farshchi
    Rokhsareh Aghili
    Maryam Oskuee
    Marjan Rashed
    Sina Noshad
    Abbas Kebriaeezadeh
    Maryam Kia
    Alireza Esteghamati
    [J]. BMC Endocrine Disorders, 16
  • [2] Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
    Farshchi, Amir
    Aghili, Rokhsareh
    Oskuee, Maryam
    Rashed, Marjan
    Noshad, Sina
    Kebriaeezadeh, Abbas
    Kia, Maryam
    Esteghamati, Alireza
    [J]. BMC ENDOCRINE DISORDERS, 2016, 16
  • [3] Cost-effectiveness of biphasic insulin aspart 30 vs. human premix insulin in type 2 diabetes from the payer's perspective in Bulgaria
    [J]. Valov, V. (vasv@novonordisk.com), 1600, Diagnosis Press Limited. (26):
  • [4] COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VS. HUMAN PREMIX INSULIN IN TYPE 2 DIABETES FROM THE PAYER'S PERSPECTIVE IN BULGARIA
    Valov, Vasil
    Palmer, James
    Czech, Marcin
    Savova, Alexandra
    Petrova, Guenka
    [J]. BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2012, 26 (02) : 2937 - 2944
  • [5] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
    Lynch, M.
    Scheijbeler, H.
    Kotchie, R.
    Neilsen, S.
    White, J.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
  • [6] Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US
    Ray, J. A.
    Valentine, W. J.
    Roze, S.
    Nicklasson, L.
    Cobden, D.
    Raskin, P.
    Garber, A.
    Palmer, A. J.
    [J]. DIABETES OBESITY & METABOLISM, 2007, 9 (01): : 103 - 113
  • [7] Cost-effectiveness of Biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting
    Aristides, M.
    Kotchie, R.
    Nielsen, C.
    Valentine, W. J.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
  • [8] PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
    Aagren, M.
    Thomsen, T. L.
    Knudsen, V. K.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A10 - A10
  • [9] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [10] Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes
    Valentine, William J.
    Pollock, Richard F.
    Plun-Favreau, Juliette
    White, Jeremy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1399 - 1412
12345